Open AccessA randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Author(s) -
Jill Gilbert,
Michael J. Schell,
Xiuhua Zhao,
Barbara A. Murphy,
Tawee Tanvetya,
Marino E. Leon,
D. Neil Hayes,
Missak Haigentz,
Nabil F. Saba,
Jorgé Nieva,
Justin A. Bishop,
David Sidransky,
Rajani Ravi,
Atul Bedi,
Christine H. Chung
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ma1w-h811
Subject(s) - cetuximab , sorafenib , medicine , oncology , head and neck squamous cell carcinoma , head and neck , head and neck cancer , basal cell , phases of clinical research , radiation therapy , clinical trial , cancer , surgery , hepatocellular carcinoma , colorectal cancer